Health outcomes in type 2 diabetes

International Journal of Clinical Practice

Volumn , Issue , 2000, Pages 46-53

  Sethu, S ^a   Reddy, K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33749224189     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ratner RE. Long-term health care outcomes in diabetes: economic and political implications. Endocrinol Metab Clin North Am 1997; 26: 487-498.
2. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. J Am Med Assoc 1999; 281: 1900-1905.
3. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999; 15: 205-218.
4. Van der Does FE, De Neeling JN, Snoek FJ et al. Symptoms and well-being in relation to glycémie control in type II diabetes. Diabetes Care 1996; 19: 204-210.
5. Rose M, Burkert U, Scholler G, Schirop T, Danzer G, Klapp BF. Determinants of the quality of life of patients with diabetes under intensified insulin therapy. Diabetes Care 1998; 21: 1876-1885.
6. Hirsch A. Diabetes care in Germany: new roles for professionals and patients. Diabetes Spectrum 2000; 13: 3-9.
7. Testa MA. Quality of life assessment in diabetes research: interpreting the magnitude and meaning of treatment effects. Diabetes Spectrum 2000;13:29-35.
8. Eddy DM. Connecting value and costs: whom do we ask and what do we ask them? J Am Med Assoc 1990; 264: 1737-1739.
9. McNeil BJ, Pauker SG, Sox HC, Tversky A. On the elicitation of preferences for alternative therapies. N Eng/ J Med 1982; 306: 1259-1262.
10. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to their Development and Use. Oxford Medical Publications. 1989.
11. Eddy DM. Assessing Health Practices & Designing Practice Policies: the Explicit Approach. American College of Physicians. 1992.
12. Paalman M, Bekedam H, Hawken L, Nyheim D. A critical review of priority setting in the health sector: the methodology of the 1993 World Development Report. Health Policy Planning 1998; 13: 13-31.
13. Sculpher M.The cost effectiveness of preference based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia. Health Econ 1998; 7: 129-142.
14. Gyrd-Hansen D, Sogaard J. Discounting lifeyears: whither time preference? Health Econ 1998; 7: 121-127.
15. Dolan P. The measurement of individual utility and social welfare. J Health Econ 1998; 17: 39-52.
16. Mehlman MJ, Durchslag MR, Neuhauser D. When do health care decisions discriminate against persons with disabilities? J Health Politics Policy Law 1997; 22: 1385-1411.
17. Orentlicher D. Psychosocial assessment of organ transplant candidates and the Americans with Disabilities Act. Gen Hosp Psych 1996; 18(Suppl6):5S-12S.
18. Kopelman LM. Ethical assumptions and ambiguities in the Americans with Disabilities Act. J Med Phil 1996; 21: 187-208.
19. Cutter MA. Ambiguities and irresolvable tensions in the ADA. J Med Phil 1996; 21: 225-235.
20. Murray CJ. Acharya AK. Understanding DALYs. J Health Econ 1997; 16: 703-730.
21. Eastman RC, Javitt JC. Herman WH et al. Model of complications of NIDDM. II Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20: 735-744.
22. Hermann WH, Dasbach EJ, SongerTJ, Eastman RC. The cost-effectiveness for intensive therapy for diabetes mellitus. Endocrinol Metab Clin North Am 1997; 26: 679-695.
23. Malmberg K. Ryden L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
24. Shichiri M. Kishikawa H. Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(Suppl 2): B21-B29. (Abstract)
25. Okhubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995: 28: 103-117.
26. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.